Yahoo
NasdaqCM - Delayed Quote USD

XTL Biopharmaceuticals Ltd. (XTLB)

1.6100 -0.1500 (-8.52%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for XTLB
  • Previous Close 1.7600
  • Open 1.6500
  • Bid 1.6600 x 200
  • Ask 2.2700 x 1000
  • Day's Range 1.6100 - 1.6900
  • 52 Week Range 1.6100 - 5.6400
  • Volume 8,599
  • Avg. Volume 7,970
  • Market Cap (intraday) 3.957M
  • Beta (5Y Monthly) 0.43
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3600
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.

www.xtlbio.com

4

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .

YTD Return

XTLB
42.50%
TA-125 (^TA125.TA)
7.70%

1-Year Return

XTLB
66.18%
TA-125 (^TA125.TA)
17.90%

3-Year Return

XTLB
50.91%
TA-125 (^TA125.TA)
137.56%

5-Year Return

XTLB
89.46%
TA-125 (^TA125.TA)
0.00%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY16
Revenue --
Earnings --
Profit Margin 0.00%

Q2

FY15

Q3

FY15

Q4

FY15

Q1

FY16

0
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -21.01%

  • Return on Equity (ttm)

    -29.30%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -759k

  • Diluted EPS (ttm)

    -0.3600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    76k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -2.12M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: